Hemoglobin-based oxygen carriers for reversing hypotension and shock: 'NO' way, NO

摘要

EFFORTS to develop a blood substitute, especially for therapy of hemorrhagic shock, have been ongoing. Most clinical trials have focused on hemoglobin-based oxygen carriers (HBOCs) rather than perfluorochemical derivatives. Although HBOCs are purified, synthesized, or modified hemoglobins from human, bovine, or recombinant sources, they most often originate from human senescent blood. ' Traditional thinking supports the idea that HBOCs may facilitate volume expansion and stabilize shock patients until erythrocytes become available. Unfortunately, it is not that simple.